Haleon PLC

Haleon Plc provides personal healthcare products. The firm focus on consumer healthcare and driven by its purpose of delivering better everyday health with humanity. Its brands are built on science, innovation and human understanding and are trusted by millions of consumers globally. The company is headquartered in Brentford, the United Kingdom.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Haleon Plc engages in the provision of personal healthcare products. The firm focuses on consumer healthcare. It operates under the following geographical segments: North America, EMEA and LatAm, and Asia Pacific. The company was founded on July 18, 2022 and is headquartered in Weybridge, the United Kingdom.

It's a big day for GSK spin-out Haleon. An overhang from the combined 45% stake owned by former parents GSK and Pfizer could start to come into play.

Haleon, US inflation the standouts for Thursday

Pfizer

Looming over Haleon PLC (LSE:HLN, NYSE:HLN) as it reports third-quarter numbers on Thursday 10 November are a couple of big issues.  The date itself is important, and this is when an overhang from the combined 45% stake owned by former parents GSK PLC (LSE:GSK, NYSE:GSK) and Pfizer PLC could start to come into play.

Haleon third-quarter update is big date for Pfizer stock overhang

Not for release, publication or distribution, directly or indirectly, in or into any jurisdiction into which such distribution would be unlawful. This notice is for informational purposes only and does not constitute an offer to purchase, or a solicitation of an offer to sell, any securities.

Haleon plc Announces Expiration and Results of Exchange Offers for Certain Series of Notes Issued in Private Placements in Connection with the Separation from GSK

Microsoft

-          On World Sight Day, Haleon and Microsoft are launching a joint effort to make health products more accessible for people who are blind or have low vision, with artificial intelligence (AI) technology that narrates product labels. -          New enhancements in the free Microsoft Seeing AI app will help advance inclusivity and improve accessibility.

Haleon and Microsoft use AI to enhance health product accessibility for people who are blind or partially sighted

Haleon was a top FTSE 100 riser Tuesday after a bullish write-up by analysts at Barclays following a three-day road trip with  management of the consumer goods and healthcare giant. 'Equal weight' is the investment view but the price target is 347p or 24% higher than today's 276.4p, up 2%.

Haleon sales targets impress Barclays

Haleon plc Announces Exchange Offers for Certain Series of Notes Issued in Private Placements in Connection with the Separation from GSK

AstraZeneca

British American Tobacco

Ferguson Enterprises Inc

GlaxoSmithKline

As the pound crashed following Kwasi Kwarteng's quasi-infamous ‘mini' budget, many crafty currency speculators made a quick fortune, while savvy stock market investors are still mulling which companies are likely to benefit most. Sterling has never been so weak, which in theory should make products sold by UK exporters potentially very much more attractive.

AstraZeneca, BAT, Ferguson, 4imprint and other exporters get double-benefit from sterling crash

Results from Haleon PLC (LSE:HLN, NYSE:HLN) and its rejection of GSK and Pfizer's request for indemnification impressed analysts UBS, who said this should allow the focus to return to the consumer healthcare group's "compelling prospects". Barclays, however, noted that GSK has contested Haleon's stance, saying “we do not agree with Haleon's position given we believe there are grounds for us to bring indemnification claims regarding certain potential liabilities (including against Haleon)” in a statement emailed out by investor relations.

Haleon impresses UBS but Barclays 'prefers to wait until Zantac visibility improves'

Haleon PLC (LSE:HLN, NYSE:HLN) shares recouped some of their losses since being spun out of GSK earlier this year as the consumer healthcare group rejected any liability in the Zantac lawsuits that have hit its parent hard. As well as publishing its maiden interim results, including a 13.4% increase in revenues £5.2bn and a 22% jump in profits, the FTSE 100-listed group said it had rejected requests from GSK and Pfizer to provision for costs related to the Zantac lawsuits in the US.

Haleon impresses with results and rejection of indemnity requests from GSK and Pfizer

Haleon (LON: HLN) share price tilted upwards on Tuesday after the company published mild financial results. The stock rose to a high of 267p, which was slightly above Friday's low of 260p.

Haleon share price: Inverted H&S points to a strong rebound

Haleon PLC (LSE:HLN, NYSE:HLN) reported a 22% increase in profits in its first set of results after being spun out of GSK, while adding that positive momentum seen in the first half has slowed very slightly in the third quarter. The FTSE 100-listed consumer healthcare group said it still maintained its guidance for full-year organic sales growth of 6-8% and that the business is “well positioned to navigate the current macro-economic challenges including rising inflation and the potential impact this may have on consumer behaviour in the future”.

Haleon says positive momentum continuing, albeit at slower rate

Haleon on Tuesday said it had notified GSK and Pfizer that it had rejected their requests for indemnification in relation to U.S.-based litigation over the heartburn drug, Zantac.

Haleon rejects Zantac indemnification requests from GSK, Pfizer

Haleon PLC (LSE:HLN, NYSE:HLN) will report its first results as a standalone business on Tuesday, after being spun out of GSK PLC (LSE:GSK, NYSE:GSK) in the summer as the largest newcomer on the London Stock Exchange for over a decade. Listed on the FTSE 100 and on the NYSE, the group, in which American giant Pfizer also has a significant stake, is one of the world's largest makers of consumer healthcare products, owning brands from Sensodyne and Aquafresh toothpaste, Voltarol and Panadol pain relief, to as respiratory, digestive health, vitamins and supplements.

Haleon half-year results will reveal if its brands are resisting trading-down effect

Haleon is a result of a demerger of the consumer business from GSK. It contains consumer-facing brands like Voltaren, some supplements, and various well-known toothpaste names.

Haleon Resistant To Consumer Pains

Haleon has tumbled 20% since trading began in July. The stock is undervalued relative to its peers.

Haleon: Undervalued With Clear Catalyst Ahead

Haleon is the spin-off of GSK plc's consumer healthcare unit. A market-leading brand portfolio supports a positive long-term outlook.

Haleon plc: Bullish On The Market's Newest Consumer Healthcare Blue Chip

Johnson & Johnson

Sanofi

Concerns over potential liability for a medication purported to cause cancer sliced billions off the value of several manufacturers of the drug in the past week. But were the cuts too deep?

Potential Lawsuits Causing Zantac Manufacturers Heartburn

Cardinal Health

Cincinnati Financial

Canadian Imperial Bank of Commerce

Cisco Systems

First Bancorp

Fulton Financial

Genuine Parts

Huntington Bancshares

Iron Mountain

Illinois Tool Works

Leggett & Platt

Realty Income Corp

Orion Office REIT

Occidental Petroleum

Paramount Global

Philip Morris

Schlumberger

TotalEnergies SE

Our total dividend income decreased from $771.96 received in July 2021. Canadian Imperial takes the crown for the largest dividend payment of the month.

Bert's July Dividend Income Summary | Dividend Investing 2022

Investors are bracing for billions of dollars in losses due to lawsuits filed over the heartburn drug Zantac.

Zantac Lawsuits Tank Pharma Stocks As Haleon, GSK, Sanofi Issue Defense

Big pharma stocks, such as Glaxo (GSK), Sanofi (SNY), Pfizer (PFE) and Consumer stock Haleon (HLN), decline due to the litigation surrounding the heartburn drug Zantac (ranitidine).

PFE, GSK & Other Pharma Stocks Hit by Zantac Litigation

Thousands of lawsuits have been filed against companies including Sanofi, GlaxoSmithKline, Haleon and Pfizer accusing them of failing to properly warn users of the recalled heartburn drugs' health risks.

Drugmaker stocks slammed over Zantac lawsuit concerns

GSK, Sanofi and Haleon shares stabilise after Zantac litigation slump

GSK PLC (LSE:GSK, NYSE:GSK) and Haleon PLC (LSE:HLN, NYSE:HLN) were the biggest FTSE 100 fallers on Thursday amid investor concerns surrounding US lawsuits over heartburn drug, which was withdrawn from the market in 2019 on cancer fears. Shares in pharma giant GSK, which specialises in infectious diseases, HIV, oncology and immunology, sunk 8.8% to 1,419p, while its recent consumer healthcare spinoff declined 7.7% to 258p on the news.

GSK and Haleon given headache by cancer-linked heartburn drug

Pharmaceutical stocks GSK, Sanofi and Haleon extended deep losses Thursday amid looming litigation around recalled heartburn drug Zantac. The post Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms appeared first on Investor's Business Daily.

Pharma Stocks GSK, Sanofi And Haleon Lose Billions As Zantac Trial Looms

Haleon - GSK's recently spun off consumer health unit - is not a party to the U.S. litigation focused on the heartburn medicine Zantac, a spokesperson told Reuters on Thursday.

News for Haleon PLC Stock (HLN)